Finpros: Uses, Dosage & Side Effects

What Is Finpros and What Is It Used For?

Finpros contains the active substance finasteride, a synthetic 4-azasteroid compound that acts as a competitive and specific inhibitor of the intracellular enzyme 5-alpha reductase type II. This enzyme is responsible for converting testosterone, the primary circulating androgen in men, into dihydrotestosterone (DHT). While testosterone is important for many physiological functions, it is DHT that serves as the principal androgen driving the growth and development of the prostate gland. In benign prostatic hyperplasia, the prostate gland gradually enlarges due to the stimulatory effects of DHT on prostatic tissue, leading to compression of the urethra and a range of troublesome urinary symptoms collectively known as lower urinary tract symptoms (LUTS).

The prostate gland normally weighs approximately 20 grams in healthy young men but can grow to 50 grams or more in men with BPH. This enlargement does not occur uniformly; rather, it is the periurethral transitional zone of the prostate that tends to enlarge most significantly, creating a mechanical obstruction to urine flow. The resulting symptoms include difficulty initiating urination (hesitancy), a weak or interrupted urinary stream, frequent urination (especially at night, known as nocturia), urgency, the sensation of incomplete bladder emptying, and in some cases, acute urinary retention — a medical emergency in which the patient is completely unable to pass urine.

Finasteride addresses the underlying hormonal mechanism driving BPH by reducing circulating DHT levels by approximately 70% and intraprostatic DHT levels by up to 90%. This dramatic reduction in DHT causes the enlarged prostate to gradually shrink, typically by 20–30% over 6 to 12 months of treatment. As the prostate volume decreases, the mechanical obstruction of the urethra is relieved, resulting in improved urinary flow rates, reduced symptom severity, and a lower risk of disease progression.

The clinical efficacy of finasteride 5 mg for BPH has been established through several landmark randomized controlled trials. The Proscar Long-Term Efficacy and Safety Study (PLESS) was a 4-year, double-blind, placebo-controlled trial involving 3,040 men with moderate to severe BPH symptoms and prostate enlargement. The study demonstrated that finasteride significantly reduced prostate volume (by approximately 18%), improved maximum urinary flow rate (by approximately 1.9 mL/s), and reduced the International Prostate Symptom Score (IPSS) compared with placebo. Critically, finasteride reduced the risk of acute urinary retention by 57% and the need for BPH-related surgery by 55% over the 4-year study period.

The Medical Therapy of Prostatic Symptoms (MTOPS) trial further evaluated finasteride in combination with the alpha-blocker doxazosin in 3,047 men over an average of 4.5 years. This study found that combination therapy was significantly more effective than either drug alone at preventing clinical BPH progression, defined as a sustained increase of at least 4 points in the IPSS, acute urinary retention, urinary incontinence, renal insufficiency, or recurrent urinary tract infections. Combination therapy reduced the risk of overall clinical progression by 66%, compared with 34% for finasteride alone and 39% for doxazosin alone.

Finasteride 5 mg is indicated for the treatment and control of BPH in men with an enlarged prostate gland. It is most effective in patients whose prostate volume is 40 mL or greater, as these individuals have the highest androgen-dependent component to their prostatic enlargement. The medication is intended for long-term use, and discontinuation of treatment typically leads to reversal of the therapeutic effects within 6 to 8 months, with the prostate returning to its pre-treatment size.

What Should You Know Before Taking Finpros?

Contraindications

Finpros should not be used in certain situations where the risks outweigh the potential benefits. Understanding these contraindications is essential for safe prescribing and patient safety. The following conditions represent absolute contraindications to the use of finasteride 5 mg:

• Hypersensitivity: Patients with a known hypersensitivity to finasteride or any of the excipients contained in the film-coated tablet should not take this medication. Allergic reactions, while rare, can include rash, pruritus, urticaria, and swelling of the lips, tongue, throat, or face (angioedema).
• Women and children: Finpros is not indicated for use in women or pediatric patients. It is a treatment specifically for adult men with BPH.
• Pregnancy and potential pregnancy: Finasteride is classified as FDA Pregnancy Category X, meaning it is contraindicated in women who are or may become pregnant. The drug inhibits the conversion of testosterone to DHT, which is essential for the normal development of male external genitalia during fetal development. Exposure to finasteride during pregnancy can cause abnormalities of the external genitalia (ambiguous genitalia) in male fetuses.

Warnings and Precautions

Several important warnings and precautions should be considered before and during treatment with Finpros. Healthcare providers should carefully evaluate each patient and discuss these points thoroughly:

Prostate-Specific Antigen (PSA) and Prostate Cancer Screening: Finasteride causes a decrease in serum PSA levels of approximately 50% in men with BPH, even in the presence of prostate cancer. This reduction means that a PSA value that falls within the “normal” range may actually be masking an elevated true PSA level. For the purposes of prostate cancer screening, any PSA measurement obtained while a patient is taking finasteride should be doubled (multiplied by 2) to compare it with normal reference ranges. It is critical that all healthcare providers involved in a patient’s care are aware that the patient is taking finasteride so that PSA results can be correctly interpreted. A sustained rise in PSA while on finasteride therapy may signal the presence of prostate cancer and should be carefully evaluated.

Mood Changes and Depression: Post-marketing reports have described mood changes, including depressed mood and, rarely, suicidal ideation in patients treated with finasteride 5 mg. While a causal relationship has not been established, patients should be monitored for mood changes and advised to seek medical attention if they experience depressive symptoms. This concern has been the subject of ongoing pharmacovigilance review by regulatory agencies including the FDA and EMA.

Male Breast Cancer: Rare cases of male breast cancer have been reported in men taking finasteride 5 mg during post-marketing surveillance. Patients should be instructed to promptly report any changes in their breast tissue, such as lumps, pain, gynecomastia, or nipple discharge, to their healthcare provider for evaluation. The relationship between finasteride use and male breast cancer has not been definitively established, but the potential risk warrants awareness.

Hepatic Impairment: Finasteride is extensively metabolized in the liver by the cytochrome P450 3A4 (CYP3A4) enzyme system. Patients with hepatic impairment may have elevated plasma concentrations of finasteride due to decreased metabolic clearance. While no formal dose adjustment guidelines exist for hepatic impairment, caution is advised in patients with liver disease, and liver function should be monitored.

Pregnancy and Breastfeeding

Finpros is absolutely contraindicated in women who are pregnant or may become pregnant. Finasteride is a potent inhibitor of DHT, which is essential for normal male fetal development, particularly the differentiation of the external genitalia. Animal studies have demonstrated that exposure to finasteride during fetal development causes abnormalities of the external genitalia in male offspring, including hypospadias and decreased anogenital distance.

Women of childbearing age must not handle crushed or broken Finpros tablets. The active substance can be absorbed through the skin, and even small amounts of finasteride may pose a risk to a male fetus. Intact film-coated tablets are safe to handle, as the coating prevents contact with the active substance during normal handling. If a pregnant woman or a woman of childbearing potential comes into contact with the active ingredient through a crushed or broken tablet, she should wash the affected area immediately with soap and water and seek medical advice.

Finasteride has been detected in the semen of men taking the medication. The amount present in semen is very small (estimated at less than 0.001% of the 5 mg dose) and is not expected to pose a risk to a male fetus through vaginal exposure. However, patients whose female partners are or may become pregnant should be aware of this and may wish to discuss it with their healthcare provider. Use of a condom during sexual intercourse is recommended as a precautionary measure.

How Does Finpros Interact with Other Drugs?

Finasteride has a favorable drug interaction profile compared with many other medications. The enzyme primarily responsible for its metabolism is CYP3A4, and finasteride does not appear to significantly affect the metabolism of other drugs processed by the cytochrome P450 system. However, there are several interactions and co-administration considerations that healthcare providers and patients should be aware of:

Clinically Relevant Interactions

Combination Therapy with Alpha-Blockers

The most clinically important drug interaction for finasteride is not a harmful one but rather a beneficial therapeutic combination. The combination of finasteride with an alpha-adrenergic blocker (such as tamsulosin, doxazosin, or alfuzosin) is a well-established and guideline-recommended treatment strategy for men with moderate to severe BPH, particularly those with prostate volumes of 40 mL or greater. Alpha-blockers provide rapid symptomatic relief (within days to weeks) by relaxing smooth muscle in the prostate and bladder neck, while finasteride addresses the underlying hormonal mechanism driving prostate growth. The MTOPS trial demonstrated that this combination approach reduced the risk of overall BPH clinical progression by 66%, significantly more than either drug used alone.

The European Association of Urology (EAU) and the American Urological Association (AUA) both recommend combination therapy with a 5-alpha reductase inhibitor and an alpha-blocker for men with moderate to severe LUTS and demonstrable prostatic enlargement, particularly when long-term treatment is planned. Patients initiating combination therapy should be counseled about the potential for orthostatic hypotension (dizziness upon standing) associated with alpha-blockers, especially during the first few days of treatment or after dose adjustments.

Effect on Laboratory Tests

In addition to its effect on serum PSA levels (reducing them by approximately 50%), finasteride can also affect other laboratory markers. Serum DHT levels decrease by approximately 70%, while testosterone levels may increase by approximately 10–20% but remain within the normal physiological range. Finasteride does not affect levels of cortisol, thyroid-stimulating hormone, thyroxine, or lipid profiles. These effects should be considered when interpreting laboratory results for patients on finasteride therapy.

What Is the Correct Dosage of Finpros?

Adults

Clinical trials have shown that the 5 mg dose provides optimal suppression of intraprostatic DHT levels. Lower doses (such as 1 mg, which is used for male pattern hair loss) provide insufficient DHT suppression in the prostate to achieve meaningful clinical benefits for BPH. The 5 mg dose reduces serum DHT by approximately 70% and intraprostatic DHT by up to 90%, resulting in clinically significant prostate volume reduction.

Treatment with finasteride is intended to be long-term. Patients should understand that BPH is a chronic, progressive condition and that discontinuation of finasteride typically leads to reversal of its beneficial effects within 6 to 8 months. Early withdrawal of treatment, before the full therapeutic effect has been realized, may lead patients to conclude incorrectly that the medication is ineffective. Healthcare providers should set appropriate expectations regarding the timeline for symptom improvement.

Children

Finpros is not indicated for use in children or adolescents. BPH is a condition that affects adult men, typically those over the age of 50, and finasteride has not been studied in the pediatric population for any indication. The safety and efficacy of finasteride 5 mg in patients under 18 years of age have not been established. Given the critical role of DHT in normal male sexual development during puberty, the use of 5-alpha reductase inhibitors in children and adolescents would be inappropriate and potentially harmful.

Elderly

No dose adjustment is required for elderly patients. Although pharmacokinetic studies have shown that the elimination rate of finasteride is somewhat decreased in men over the age of 70 (with a half-life of approximately 8 hours compared to 6 hours in younger men), this difference is not clinically significant and does not necessitate a change in dosage. The PLESS trial and other major clinical studies enrolled significant numbers of elderly patients, and the efficacy and safety profile of finasteride was consistent across age groups. Elderly patients often have the greatest benefit from finasteride treatment, as they tend to have larger prostates and more severe symptoms.

Missed Dose

If you miss a dose of Finpros, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. Because finasteride has a biological effect that persists for several days (due to the slow dissociation of the drug from the 5-alpha reductase enzyme), missing a single dose occasionally is unlikely to have a significant impact on the overall therapeutic benefit. However, regular daily dosing is important for maintaining consistent DHT suppression and achieving optimal clinical outcomes.

Overdose

In clinical studies, single doses of finasteride up to 400 mg and multiple daily doses of up to 80 mg for three months did not result in clinically significant adverse effects. There is no specific antidote for finasteride overdose. In the event of an overdose, standard supportive care measures should be employed. Because finasteride is highly bound to plasma proteins (approximately 90%), hemodialysis is not expected to significantly enhance drug elimination. Patients who have taken an overdose should be monitored and treated symptomatically as appropriate.

What Are the Side Effects of Finpros?

Like all medicines, Finpros can cause side effects, although not everybody gets them. The side effect profile of finasteride 5 mg has been extensively characterized through clinical trials involving thousands of patients and decades of post-marketing surveillance. In the pivotal PLESS trial, finasteride was generally well tolerated, with the majority of reported side effects being sexual in nature and typically mild in severity. It is important to understand that many of the symptoms reported during finasteride treatment (such as erectile dysfunction and decreased libido) are also common in the aging male population and occur in placebo groups at significant rates.

The following side effects are organized by frequency according to the internationally recognized classification system used in prescribing information:

Sexual Side Effects in Detail: The sexual side effects of finasteride have been the subject of extensive clinical investigation and public discussion. In the PLESS trial, the incidence of drug-related sexual adverse events was highest during the first year of treatment and decreased with continued therapy. By years 2 through 4 of the study, the incidence of new sexual adverse events in the finasteride group was similar to that in the placebo group. In the majority of patients who experienced sexual side effects, these effects resolved either during continued treatment or after discontinuation of the drug.

A topic that has received considerable attention in the medical literature and popular media is the concept of “post-finasteride syndrome” (PFS), which refers to the reported persistence of sexual, neurological, and psychological symptoms after discontinuation of finasteride. While patient reports of persistent symptoms are acknowledged and taken seriously by the medical community, regulatory agencies including the FDA and EMA have noted that a definitive causal relationship between finasteride and persistent sexual dysfunction after drug cessation has not been established through controlled studies. Research into this topic is ongoing, and patients should discuss any concerns with their healthcare provider.

Breast Changes: Gynecomastia (enlargement of breast tissue) and breast tenderness have been reported uncommonly with finasteride use. In most cases, these effects resolved after discontinuation of the medication. Patients should report any breast changes, lumps, nipple discharge, or pain to their healthcare provider promptly, as rare cases of male breast cancer have been reported during post-marketing surveillance. The relationship between finasteride and breast cancer has not been definitively established.

Mood and Psychological Effects: Post-marketing reports have described mood changes, including depressed mood and, rarely, suicidal ideation in patients taking finasteride. A systematic review and meta-analysis published in the Journal of Urology found that the overall risk of depression with finasteride use was low but statistically detectable in some study populations. Patients and their family members should be aware of this potential risk and should promptly report any changes in mood, motivation, or emotional wellbeing to their healthcare provider.

How Should You Store Finpros?

Proper storage of medications is essential to maintain their effectiveness and safety throughout the treatment period. Finpros film-coated tablets should be stored under the following conditions to ensure pharmaceutical quality:

• Temperature: Store at room temperature, not exceeding 30°C (86°F). Do not refrigerate or freeze.
• Moisture protection: Keep the tablets in the original blister packaging or container until use. Do not transfer tablets to other containers that may not provide adequate moisture protection.
• Light protection: Protect from direct sunlight and excessive light exposure. Store in the original carton when not in use.
• Child safety: Keep out of the sight and reach of children. The film coating of the tablet prevents direct contact with the active substance, but as with all medications, children should not have unsupervised access.
• Expiry date: Do not use Finpros after the expiry date stated on the carton and blister pack. The expiry date refers to the last day of the indicated month.

Do not dispose of medications via household waste or wastewater. Ask your pharmacist about proper disposal methods for unused or expired medications. Appropriate disposal helps protect the environment and prevents accidental exposure. In many countries, pharmacies participate in medication take-back programs that ensure safe disposal of unused drugs.

If you notice any change in the appearance of the tablets (such as discoloration, crumbling, or an unusual odor), do not take them and consult your pharmacist. The film-coated tablets should appear uniform in color and shape. Any visible damage to the film coating may allow exposure of the active substance, which is of particular concern because of the risk that crushed or broken tablets pose to pregnant women or women of childbearing potential who may handle them.

What Does Finpros Contain?

Active ingredient: Each film-coated tablet contains 5 mg of finasteride. Finasteride is a synthetic 4-azasteroid compound with the chemical name N-(1,1-dimethylethyl)-3-oxo-(5α,17β)-4-azaandrost-1-ene-17-carboxamide. It has a molecular weight of 372.55 and the molecular formula C₂₃H₃₆N₂O₂. Finasteride is a white crystalline powder that is soluble in chloroform and lower alcohol solvents but practically insoluble in water.

Excipients (inactive ingredients): The film-coated tablet formulation typically includes excipients that serve various pharmaceutical functions:

• Tablet core: Lactose monohydrate (filler/diluent), microcrystalline cellulose (binder), pregelatinized starch (disintegrant), sodium starch glycolate (disintegrant), sodium lauryl sulfate (wetting agent), and magnesium stearate (lubricant).
• Film coating: Hypromellose (film-forming agent), titanium dioxide E171 (opacifier/colorant), talc (anti-adherent), iron oxide yellow E172 (colorant), and macrogol/polyethylene glycol (plasticizer). The film coating serves to protect the tablet, facilitate swallowing, and critically prevent direct contact with the active substance during handling.

Patients with known allergies or intolerances to any of these excipients should inform their healthcare provider before starting treatment. Notably, Finpros tablets contain lactose monohydrate; patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medication.

The film-coated tablet is designed to be taken whole. The coating is not merely cosmetic; it serves an important safety function by preventing skin contact with the active substance. This is particularly important because finasteride can be absorbed through the skin and may pose a risk to pregnant women who might handle the medication. For this reason, the tablets should never be crushed, broken, or split.